vaccine-preventable subject free possible current such assert subsequent additional digital re-hosted educational non-commercial computer-extracted Computer-extracted such unusual odd Original 2021-11-05 Voccine-Prevenfoble VOCCine-Prevenfoble responsible additional i /- YS-2 fourth ever-expanding least first available vaccine-preventable individual all-time series-complete unaccept- low adverse new new epidemiologic provisional available addi- complete free many many many valuable inevitable future useful day-to-day Vaccine-Preventable non-simultaneous Non-Simultaneous different same Large-Linked Vaccine-Preventable 1950-1998 Vaccine-Preventable 1992- Community-Based 152:318-20 patient 1973-1997 Other Other bacterial live human bacterial viral human oral global Last indigenous Last recombinant first Last wild-virus Acellular non-self non-self infectious own permanent infectious Vaccine-Preventable detailed basic useful Many available additional infectious basic active passive own permanent human effective few complex primary foreign “ non- such immune specific cell-mediated foreign effective live alive natural such Other such long certain effective good specific temporary immune common passive last 1-2 full-term same certain red small intravenous large whole red major human homologous homologous human heterologous human many different many different high high other smaller important human similar natural post-exposure several available Active antigen-specific cellular passive temporary active many active natural general infectious many immunologic certain many active similar natural similar natural Many maternal such nutritional basic live different available live live whole Fractional protein-based polysaccharide-based Protein-based bacterial Most polysaccharide-based cell- more similar natural better wild serial wild small large immune live ineffective such natural much milder natural adverse protein-based polysaccharide-based wild effective similar natural possible pathogenic oral yellow oral effective live identical natural wild severe certain live original disease-causing live due transplacental sensitive labile available live yellow bacterial oral fractional alive entire live present antibody-containing general protective protective second third natural humoral cellular inactivated periodic supplemental critical whole bacterial reactogenic available inactivated whole acellular typhoid pneumococcal meningococcal pneumococcal certain available pneumococcal meningococcal independent able 3-5 humoral pneumococcal meningococcal pneumococcal independent immunogenic clear inactivated “ functional little late independent pneumococcal available genetic available present live lessfunctional important appropriate Specific antibody-containing live simultaneous nonsimultaneous different subsequent same same certain such antibody-containing different subsequent same 2-3 live live live enough viral live necessary least necessary other live recent current necessary live few significant yellow non-simultaneous simultaneous simultaneous live decreased adverse simultaneous least possible local systemic feasible preferable separate eligible important appropriate recent unvaccinated vaccine-eligible same same same Non-simultaneous different different other least precau- prudent second effective oral oral other simulta- other rotavirus older vac- same circum- live live oral oral live clear other least yellow protective other live oral other same multi-dose possible up-to-date necessary normal important effective minimum important other other different acceptable other close minimum acceptable shorter day—the next necessary oral typhoid oral longer single multiple periodic dose additional single necessary oral extraneous true adverse mild self-limited unrelated specific immune second “ live long-lasting necessary dose protective second third few notable periodic additional rare older long active specific adverse extraneous primary adverse adverse true adverse general local systemic least severe frequent least frequent common adverse local such Local common such Local few rare local severe due high many common unrelated concomitant viral similar adverse frequent whole systemic adverse acellular adverse common inactivated adverse such similar natural due rare third severe allergic other such antibiotic bacterial allergic life- allergic good prior adverse public private medical serious adverse Most temporary serious adverse adverse true serious general similar serious such passive less normal present adverse high whole acellular subsequent high adverse few true severe severe prior permanent further pertussis-containing shock-like hypotonic additional available chronic such short-gut permanent temporary live temporary severe recent antibody- severe allergic medical severe urticaria appropriate rare common animal yellow able anaphylactic anaphylactic-like adverse reasonable yellow Several recent severe severe allergic prior pregnant theoretical live theoretical pregnant severe due uncontrolled oral live next significant congenital immunosuppressed same live least large live weight such short dose topical poor functional general same other inactivated healthy negative older severe severe due topical short unrelated severe acute adverse severe live inactivated common such Recent oral appropriate certain true Such common invalid minor anaphylactic certain mild such low-grade upper large young large small such mild Low-grade necessary antibiotic antiviral adverse live pregnant breast-feeding noncommunicable uncommon immune prior greater other fetal passive vaccine-preventable maternal low-grade upper • multiple prior subsequent adverse chronological other high-risk positive chronic non-severe non-specific available Non-anaphylactic such true anaphylactic relevant oral personal same most false negative same more most 4-6 routine available such available serious adverse difficult few acute necessary severe time-efficient generic Most familiar minor medical last open-ended previous additional such high immune oral last last healthy last live last few unreported pregnant pregnant pregnant necessary pregnant American 2959-63 preschool-aged 1991-1992 43:709-11,717 148:943-9 important public safe efficacious 2:18-25 Vaccine-preventable wild current * suboptimal 1996-97 other lower flu pneumococcal racial greater inner second optimal potential different easier national effective great least Sustainable high one-time short-term effective available potential ill-conceived wrong well-suited low particular well-suited poor new current most sufficient unvaccinated low knowledgeable ready new capable new public private diagnostic specific practice-based more public private effective sustainable first public median public measles-containing recent public several significant positive Other more gradual consistent public private median up-to-date second wide semi- annual congressional federal annual public public private private public personal technological medical • important sweeping governmental individual personal technological whole-hearted intense subtle assessment persuasive critical technologic practice-based medical essential high own several clinic manual self-assessment easy many special previous useful such last other specific adequate important laundry diagnostic manual available easy special specific Other individual useful necessary necessary appropriate positive private public academic non-physician internal general most universally-recommended entire medical inter-professional Well-designed effective more detailed diagnostic single systemic eligible last “ diagnostic effective specific bad bad pre-arranged circumscribed over-riding specific friendly national competitive scramble last relative useful wide public likely intrinsic extrinsic useful significant unlikely special powerful Pre-arranged necessary credible well-communicated positive individual individual same professional clerical light professional powerful Most improved useful sustainable able other professional free low knowledgeable ready new important next best new powerful believable relevant educational negative true assessment diagnostic cross- new other follow-up relative common common public appropriate state-wide regional local clerical such American pleasant extensive specific non- simultaneous appropriate influential easy available sustainable improved late influential own successful useful true dry useful attainable better high well- applicable public private tremendous intuitive good understandable available many understandable available Easy-to-read available essential medical important age-dependent front current active medical complete important school-based public community-based primary reliable possible efficient difficult powerful influenza positive initial negative other pediatric likely irrespective true necessary useful next current next next 6- due due patient many important powerful likely due due vary effective expensive • wide-spread other preventive other effective reluctant aggressive expensive elaborate card-file weekly many aggressive recent computer-generated wide-spread aggressive overdue local technical public private federally-funded public local aggressive private additional on-time significant public private key other preventive recent preventive vaccine-preventable contagious individual due due different overall computer-generated past-due red senior vital nurse effective knowledgeable effective related such eligible such primary public public due due computer-generated eligible primary public simultaneous additional simultaneous injectable simultaneous immune adverse scientific available accelerated accelerated important early six-month larger child large missed several non-physician direct such other positive multi-component other effective invalid chief physical strong valuable multi-component important unlit supportive safe poor practice-based good useful useful strong wide clinical • Psychological Evidence-based 404-839-4301 aggressive definitive evidence-based possible cost- population-based preventable more late 4:186-192 practice-based performance-based elderly public 1988-1994 277:631-635 private Programmatic provider-based underimmunized cost-effective 16:28-33 primary 148:158-166 computer-generated clinic 149:902-905 computer-generated preschool-age 148:908-914 underimmunized 101:690-691 pediatric US American diphtheritic aerobic gram-positive specific bacterio- genetic severe selective contain- other severe toxigenic responsible local • gram-positive normal diphtheroid 2-6 1-10 mucous exudative 2-3 high responsible major complica- low Clinical severe toxigenic due inad- equate Clinical 2-5 1-10 mucous clinical indistinguishable common blood-tinged white nasal mild be- apparent poor systemic antibiotic common substantial systemic insidious low-grade 2-3 bluish-white small soft greyish-green black minimal forcible Extensive mem- enough severe rapid high severe submandibular anterior lymphadenopathy char- acteristic mem- cutaneous common sible high natural scal- other recent non-toxigenic general less other toxigenic Other mucous mem- vulvo-vaginal external attributable attributable local early fatal soft frequent third fifth diaphragmatic Other due overall higher little last clinical imperative presumptive critical tonsillar selective hemolytic helpful clinical multiple club-shaped Other direct clinical diagnostic antibiotic positive presumptive low non-protective anti- administra- commercial several 18-24 available antibi- adequate isola- provisional clinical appropriate maximum less contagious docu- consecutive negative less old old older 7- 10-day oral asymptomatic several anti- first cutaneous nontoxigenic clinical highest highest significant Native geographic asymptomatic high variable less more antibiotic major mor- top 1940-1998 100,000-200,000 140-150 rapid widespread late high cutaneous non-toxigenic cutaneous fre- lower socio- economic 1980-1998 0-5 1982-1997 twenty-five unimmunized immunized current inadequate many less protec- tive rare endemic American classic dis- toxigenic good Diphtheria-United 1982-1997 < 10-19-20-29 30-39 40-49 Russian many other major former entire epidemic due several routine early early toxigenic primary protective international clinical usual primary 15-18 acceptable alternative available first second third fourth third valid old first older first third dose 6-12 second primary fourth fourth optimal last protective old older least third dose subsequent ultimate first least last next frequent local adverse active less Routine 6-12 systemic uncommon systemic severe erythema common self-limited palpable several other systemic uncommon severe local high severe systemic such severe previous additional mild deliv- erable 2°-8°C 35°-46°F direct cutaneous toxigenic appropriate preliminary clinical epidemiological early presumptive least negative close other oral close nasal antibiotic unknown immediate primary current toxoid-containing recent Other adequate antibiotic additional 10-day older other preventive 1971-81 1393-7 1995-March 42:840-1 due vaccine-preventable former pandemic 4:539-50 convulsive skeletal 5th clinical fatal human same specific protective passive active gram-positive sensitive resistant usual 10-15 other infectious agricultural significant human gram-positive spore-forming human ſeawus central nervous unopposed 3-21 clinical uncommon rare common spasms 3-4 complete low several central nervous peripheral spinal sympathetic nervous typical clinical unopposed autonomic nervous further central nervous longer higher neonatal clinical same anatomic many fatal rare ear present middle cranial facial common first trismus abdominal Other 2°-4°C normal episodic rapid last several 3-4 newborn protective unhealed umbilical unsterile common rare vocal sustained nervous abnormal common Secondary hospital-acquired elderly common fatal tetanus obvious direct several gradual complete clinical protective passive due Other nosocomial higher other last dose last dose contagious necrotic foreign tetanic supportive adequate critical single available practical useful proper important active primary toxoid clean minor 0-2 uncertain prior temporary protective most populated hot organic intestinal major minor recent higher likely elective deep contagious vaccine-preventable infectious contagious early late late notifiable 500-600 50-100 constant provisional all-time older older younger last few older recent older primary 1947-1998 L-L-L-L-L-L-L-L-L-L-L-L-L-L-L-L-L-L-L 1980-1998 1982-1997 < 10-10-19-20-29-30-39 40-49-50-59 \- 1991-1994 1995-1997 | 20-59 Formalin-Inactivated high rare 1995-1997 such Other acute self-performed animal such surgical various chronic unknown safe useful prior formaldehyde-treated available equal higher single periodic older younger primary greater minimal protective protective complete clinical last last rare primary most minimal protective last routine small minimal protective other clean last least old less recommended routine primary 15-18 valid pediatric 6-8 sepa- 15-18 first second second third fourth primary less third 6-12 systemic old first older first third dose 6-12 second primary fourth adminis- fourth recom- one-third much other diphtheria-containing routine old older local higher common older first third dose 6-12 second first 11- optimal last additional least last next frequent local adverse common self-limited palpable several other systemic uncommon local tetanus- unusual extensive painful severe high severe local such generalized few peripheral neuropathy recent available brachial severe allergic previous useful appropriate severe routine minor severe passive other clean pediatric 2°-8°C 35°-46°F noncontagious 40-60 older high other preventive 1995-1997 neonatal 396-8 Red American vaccine-preventable vital 1979-1984 132-42 “ high-risk ” WHO-recommended 20th common major unimmunized major due small aerobic gram-negative fastidious special multiple antigenic active filamentous responsible clinical subsequent clinical contagious gram-negative active filamentous epithelial similar upper 1-6 • 1-2-week- Week-to-month- toxin-mediated pulmonary recent alveolar clinical insidious runny low- occasional similar common severe 1-2 second paroxysmal paroxysmal numerous due thick long characteristic high-pitched cyanotic young ill normal first same last gradual less paroxysmal subsequent many minimal indistinguishable other upper cough other susceptible unimmunized multiple highest clinical pertussis-associated common pertussis-related secondary bacterial 1990-1996 such common Other serious severe subdural due 1990-1996 m. 1-y 5-9 10-19 20-y c-tºo-tº-ºn-35,508 characteristic physical useful young atypical difficult direct successful posterior selective prepared antibiotic effective trimethoprim-sulfamethoxazole first second direct direct low variable useful clinical difficult available clinical serologic national clinical positive positive positive probable nasopharyngeal rapid sensitive available certain direct necessary bacterial antimicrobial white present classical greater medical supportive other clinical other close four- primary minimal primary human important respiratory airborne silent little rare catarrhal Secondary 1940-1998 º 1940-1950-1980-1970-1980-1990 1980-1998 ca-e- 9000- 1985-1997 < 1-4 5-9 10-19-20-29-30-39 40- -20 1985-1987 1995-1997 1995-97 | 10-yrs distinct seasonal communicable secondary unimmunized contagious catarrhal Secular common 1940-1945 annual 1980-1990 ~1 1992-1993 largest Large clear 3-5 frequent older larger recent 1985- 1995-1997 1990-1996 current clinical least inspiratory post-tussive other apparent clinical laboratory-confirmed compatible laboratory-confirmed laboratory-confirmed clinical appropriate endemic sporadic outbreak least direct nasopharyngeal low variable probable mid-1940s Whole-cellpertussis formalin-inactivated clinical current available five-dose 5-10 common subsequent observational primary whole-cell effective serious local little last adverse local such other mild severe systemic such hypotonic 0-10.5 such more purified adverse effective rare adverse fourth fifth 1991-1992 primary 1996-1997 Several acellular different fourth fifth primary 2-º.8 acellular filamentous equal perdose several 51-86 59-90 83-78 effective acellular effective whole-cell local systemic serious such high hypotonic acellular acceptable alternative available primary first 4-to 8-week fourth 6-12 third adequate fourth certain fourth fourth least least third unlikely additional fourth 12-14 necessary fourth primary younger prior first 15-18 15-18 earlier unlikely 15-18 interchangeable whole whole available mix-and-match different same possible different necessary frequent older pertussis-associated single available primary simultaneous whole oral measles-mumps- similar efficacious whole primary local other systemic adverse whole whole whole different successive possible same available available possible potential neurologic neurologic more certain neurologic uncontrolled progressive other neurologic stable neurologic idiopathic cerebral developmental full multiple smaller altered significant likely full smaller standard typical clinical such other certain assess neurologic full severe adverse additional typical clinical injected local such such low severe adverse uncommon common whole-cell self-limited symptomatic such persistent hyporesponsive whole severe such encephalopathy rare adverse available whole available whole pertussis-containing excess 0- available whole severe allergic prior due identifiable severe such due acute infrequent adverse subsequent due identifiable shock-like hypotonic-hyporesponsive inconsolable > community- wide precautionary adverse previous more additional valid due identifiable severe otheridentifiable shock-like hypotonic- hyporesponsive inconsolable more • valid 2°-8°C 35°-46°F susceptible normal other Other adverse other whole other due modern medical important greater acellular distinct many adverse critical many congenital manifest other systemic inevitable central-nervous such pyrogenic largest likely non-SIDS infantile recent responsible other more subtle neurological such infantile progressive degenerative scientific other relative less last major annual less 1977-1979 adverse major high More epidemic epidemic risk-benefit hypothetical overall annual residual annual more 10-fold Most Most weekly lengthy many unreported useful epidemiologic highest greatest severe recent • equal fewer young 1992-June 44:525-9 44:74-6 acellular adverse 14:708-19 anti-vaccine untold 351:356-61 1990-1996 Adverse Vaccine-Preventable spinal spinal classic compatible recognizable first early few next developed severe average af- increased primary paralytic effective last wild-virus global next transient gastrointestinal stable small ether-insensitive minimal formalde- paralytic local central nervous inapparent aseptic -Nonparalyticaseptic non-CNS primary multipli- gastrointestinal present little several local central nervous anterior typical polio- variable clinical sub- clinical paralytic able minor nonspecific clinical laboratory central nervous syn- abortive charac- complete less poliovirus upper gastrointestinal abdominal influenza-like able other viral aseptic several similar last complete pa- tempera- normal biphasic initial minor 1- major superficial deep asymmetrical paralytic permanent Paralytic common paralytic 1969-1979 cranial spinal paralytic cerebrospinal diagnostic flaccid genomic deter- “ wild-like possible 7-10 early high there- 4-fold white wild eradica- Indian known inapparent asymptomatic immune fecal-oral important al- oral-oral seasonal tropical infectious susceptible susceptible infectious initial least early maternal high continual paralytic rare lameness stud- immediate pre-vaccine frequent infrequent natural paralytic early paralytic last paralytic endemic wild several paralytic last imported recent direct oral Christian paralytic non-paralytic ten paralytic non-paralytic mean 1950-1998 1980-1998 general less Christian non-paralytic,7-18 non-Amish effective • local early oral poliovi- other first available vaccine-related effective protective least immune paralytic important vaccinated safe immunodeficient injec- expensive many complete local gastrointestinal wild endemic paralytic wild oral effective produc- single live oral easy expensive excellent intestinal wild important infected wild endemic other live oral lifelong wild repli- fecal oral vaccine-related new vaccine-related important 1990-1991 small uted secondary Most polio attributable secondary most high more poliovi- prob- little difficult unintended vaccine-associated paralytic effective paralytic available paralytic 1964-1998 such single intestinal inter- other second small paralytic con- Vaccine-Associated paralytic rare adverse live oral live paralytic identical present likely central nervous likely likely normal certain available paralytic older Vaccine-associated paralytic oral wide year-to-year vaccine-associated paralytic healthy average healthy immunodeficient immunodeficient re- equal other overall paralytic normal overall first other overall Sixty-five first first subsequent able revertant similar nonimmune Vaccine-Associated 1980-1994 1980-1994 effective certain sequential routine first third fourth least first small vaccine-associated paralytic highest first first live vaccine-associated sequential high individual sequential intestinal intestinal wild re-introduced sequential sched- fewer second overall sched- easier prod- admin- secondary primary sequential primary 12-18 4- first least 6-8 necessary pro- simulta- tox- highest first single significant least prior little effective acceptable acceptable endemic high intestinal desirable additional acceptable highest least • 6-18 third primary fourth little 4-6 primary all-OPV primary primary other 6-18 routine usual 6-8 rapid third fourth fourth fourth third fourth necessary pro- primary effective acceptable sched- such endemic pre- additional 6-18 4-6 all-IPV primary other first third 6-18 first second necessary immune third high preferred second third 2-8 mini- fourth fourth fourth third fourth necessary sequential preferred sched- routine all-OPV all-IPV acceptable certain 4-6 complete minimum additional re- hepati- acceptable complete necessary greater health-care possible 1-2 6-12 separate necessary necessary immune small expo- poliovi- endemic epidemic health-care close excret- specific current wild previous vaccina- available unvaccinated primary recom- feasible vaccine-associated higher 1- 2-month available least 4-8 available least available single primary further supplementary full last necessary receiv- minimal OPV-associated paralytic prompt complete sequential com- minimal local serious adverse docu- strepto- allergic rare associ- healthy available other likely such adverse vaccine-associated susceptible personal vaccine-associated paralytic complete serious adverse rare severe allergic further indi- ana- phylactic such severe mild successful immuni- mild upper local previous current antimicrobial acute immunodeficient im- due familial im- close approxi- 4-6 feasible rigorous ac- effective oral general nant immediate swallow judge- substan- tial 5-10 same dry lower frozen liquid vac- freeze-thaw total cumulative 2°-8°C 35°-46°F multiple-dose 2°-8°C red main- 2°-8°C 35°-46°F per- clear preliminary clinical epidemiological paralytic appropriate local appropriate viral paralytic immedi- vaccine-associated unvaccinated Last Last • free widespread many paralytic last indigenous wild surveil- such national last wild-virus-associated indigenous additional sive international free indigenous detailed national global many polio-endemic para- lytic global eradica- Indian international other bilateral multilateral 30-40 paralytic new new post-polio post-polio syndrome perma- nent residual post-polio oversized para- lytic tious Several post-polio 534-0475 655-5301 live oral 103:17.1-2 sequential inactivated oral 1980-1994 46:79-83 43:720-2 global 47:414-9 oral 13:926-39 paralytic polio- 1980-1991 last indigenous wild virus-associated dis- 14:568-79 new paralytic early bacterial viral parasitic fewer intestinal common severe young responsible diarrhea wide double-stranded concentric important contagious acute viral common severe Responsible > responsible predominant small uncommon important severe 1-3 Variable clinical presentation- asymptomatic most severe specific least least different responsible human other stable viable many animal distinct human villous small small systemic uncommon intestinal decreased intestinal isotonic important Cell-mediated single natural severe greater severe first asymptomatic low- severe asymptomatic severe clinical nonspecific similar other young severe severe 100,000- fatal large more physician more 20-40 severe higher severe persistent multiple available Several commercial available common human simple inexpensive sensitive Other such nucleic available recent geographic specific common recent Responsible diarrheal gastrointestinal many nonhuman rare clinical true high fecal-oral such other environmental respiratory annual epidemic seasonal unknown tropical seasonal communicable universal large | common notifiable special universal least | similar improved sufficient younger low passive maternal clinical highest asymptomatic nosocomial immunodeficiency-related responsible responsible more diarrheal seasonal direct medical total due live young new live predominant genetic different human identical various human • nosocomial important genetic human live human original identical human Rotavirus-based live low human non-human common human human citrate-bicarbonate fine fetal immune difficult significant large placebo-controlled similar effective effective severe unvaccinated effective large effective least clinical least rotavirus American routine oral first older short first first older available fewer other same oral other live same necessary second first first other usual due recent antibody- sensitive minor upper low severe immune partial limited usual available antibody- simultaneous antibody-containing parenterally-administered recent unvaccinated unvaccinated sensitive Other other common such environmental specific such immunosuppressed necessary available clinical common adverse low first attributable similar other live viral serious severe anaphylactic such such other immunosuppressive solid such immunosuppressive solid organ HIV-infected negative older viral severe gastrointestinal normal adverse general severe neurologic present possible such underlying first other minor low pre- chronic such congenital short-gut gestational available lower passive available theoretical case-by-case individual lyophilized freeze-dried separate powdered stable least 20°-25°C 68°-77°F 2°- 36°-45°F ambient 2°-25°C 36°-77°F citrate-bicarbonate stable 2°-8°C 36°-45°F such more earliest reportable medical national national specific rotavirus-compatible representative necessary national local additional vaccinestable young severe live national unusual 1483-91 561-570 1997:285-343 S118-24 high-dose rhesus-human rotavirus-based young 337:1181-7 rhesus-human severe 350:1205-9 273:1191-6 Cost-effectiveness 279:1371-6 major clinical unencapsulated capsular cerebrospinal effective bacterial other invasive bacterial serious invasive influenzae gram-negative aerobic facultative bacterial influenza influenzae gram-negative responsible different a-ſ invasive major distant polyribosyl-ribitol responsible distinct capsular invasive several normal unencapsulated frequent human non-invasive invasive exact unknown likely striking age- dependent 6-7 humoral capsular protective invasive long-term invasive anticapsular age-specific most natural 5-6 asymptomatic small common antigenic so-called anticapsular other genetic important genetic unknown single genetic many organ common invasive common clinical invasive stiff appropriate antimicrobial life-threatening focal severe common invasive common invasive effective antimicrobial effective Ampicillin-resistant common due nontypable invasive small gram-negative invasive pleural middle appropriate positive important important viable available rapid sensitive specific capsular pleural similar sensitive difficult effective third- Ampicillin-resistant common life- etiologic initial empiric respiratory firm bimodal seasonal second contagious invasive certain close day- institutional direct secondary reportable Serotype-specific most national several active younger 40-50 late less due young bacterial invasive 1987-1997 “ 200- 150- ~ Q-1 12-13-24-25-35-37-48-49 parental good unvaccinated age-dependent invasive 6-11 invasive 1996-1997 invasive less young three-dose primary Fifty-two eligible primary age- eligible unknown 1996-1997 less large low socioeconomic low parental school-aged socioeconomic chronic breast-feeding maternal invasive secondary 600-fold higher general first second third fourth secondary Most day-care low secondary effective younger older negative greater Available 1985-1988 available effective similar other polysaccharide pneumococcal meningococcal typical T-independent age- poor poor immunogenic old functional poor effective T-independent T-dependent young class-specific useful young first immunogenic active additional young distinct identical different available toxoid toxoid effective different protective primary rare invasive such sickle-cell invasive primary separate primary primary three-dose primary 12-15 primary ACIP-Recommended 12-15 optimal least previous other immunologic additional subsequent younger interchangeable protective necessary primary primary more older full current Detailed entire 2-6 12-15 current 7-11 12-18 12-14 dose 15-59 least dose 15-59 dose 2-6 12-15 PRP-OMP dose same primary 2-6 elementary necessary fourth fourth 2-6 12-15 least last 7-11 12-18 least last 12-14 unvaccinated 15-59 single 2-11 12-18 least last 12-14 unvaccinated 15-59 single unvaccinated 15-59 12-18 two- three-dose primary variable up-to-date late current c 7-1 l 7-1 licensed complete invasive protective anti-PRP invasive invasive unimmunized possible invasive older general asymptomatic older invasive high functional anatomic sickle high least licensed other licensed whole acellular possible primary whole available separate single feasible same unvaccinated 2-6 least additional 12-15 least 6-month third first single appropriate acellular fourth single whole Available initial first invasive first second third single standard immune 0-1-6 positive chronic same adequate uncommon 12-24 such adverse local systemic similar concurrent individual serious adverse severe upper-respiratory same liquid refrigeraor 2°-8°C stable reportable invasive local 5-30 adverse acute illness primary invasive such least conjugate more invasive single daily maximal < day-care controversial less optimal necessary pregnant possible more last likely same invasive necessary soft oral influenzae invasive 1994-1995 vaccine-preventable 4:229-37 older 1987-1997 47:993-8 invasive 1990-1996 47:737-40 120:184-9 Invasive older vaccine-preventable American 13:113-42 dreaded lifelong human live single-stranded structural viral important responsible viral responsible antigenic recent important short contagious viral universal fatal light systemic primary regional primary subsequent viral regional distal second initial other nasopharynx 3-4 Clinical 7-18 prodrome 2-4 1-7 high 103°-105°F mucous pathognomonic 1-2 1-2 blue-white bright red buccal maculopapular 5-6 upper next downward discrete upper 3-4 involved same Other diarrhea regional 2-3 5-7 10-12 higher • confluent 5-6 common viral bacterial common 1-15 stiff residual many 1-2 recent other higher young common rare degenerative central nervous due persistent Average month-27 insidious progressive early higher spontaneous low- birth-weight definable ontºº-ºººº pleural maculopapular petechial urticarial vesicular local severe immune young residual mild discrete short high 105°-106°F mucous certain typical several acute high severe bacterial high African important molecular geographic viral urine nasopharyngeal public viral same likely more detailed viral enzyme-linked available diagnostic susceptible wild many negative negative positive previous single diagnostic positive other positive first false-negative negative first detectable least rash clinical late available indirect possible second same same specific four-fold greater second human asymptomatic large closed late communicable > secondary susceptible 3-4 actual More highest 5-9 more 2-3 epidemic indigenous lowest annual 1980-1988 school-aged first school-aged second measles- median 1950-1998 1980-1998 1–4–1–i-1–4–1–1–1–1–1–1–1 1975-1997 s medical 1989-1991 dramatic school-aged largest first Thirty-five school-aged old Overall highest lowest non-Hispanic higher non-Hispanic measles-associated death-to-case Forty-nine fatal Sixty-four largest annual important 1989-1991 low low many large preschool-aged early preschool-type few second black likely white less 1989-1991 more high other many young due wild smaller higher wild susceptible younger many other 1993-1998 1989- due preschool-aged year-old fewer other aggressive low achievable due several large religious philosophic provisional lowest annual preschool-aged common major predominant school-aged greatest Preschool-type unvaccinated school-aged large school-aged first 1993-1998 Many due • school-aged annual school-aged involved preschool-aged annual preschool-type prominent several large preschool-aged several unvaccinated black Hispanic school-aged small largest vaccinated smaller 1989-1991 large preschool-type probable maculopapular noncontributory probable probable possible local indigenous out-of-state entire international first unique atypical wild-type original high live fewer original available live available single measles-mumps-rubella individual live vaccine- live further other recommended minimum valid freeze- sterile preservative-free small human noncommunicable primary other first first first serologic vaccine-induced lower natural serologic epidemiologic vaccine-induced long-term life-long Most vaccinated anamnestic available secondary successful minor least least other first first measles-containing early first least second first second first catch-up earlier first additional other acceptable first second possible less first medical least least measles- rubella- other acceptable pregnant medical acceptable such special other post-high educational medical international other post-high educational potential high-risk large susceptible first primary 12-15 medical immune technical other post-high other acceptable live other acceptable first prior other measles-containing first second least previous medical higher general least overall 1989-91 1993-96 medical medical 1993-1996 medical medical non- medical full non-student susceptible medical private public possible elderly low live least live second least first acceptable medical unvaccinated prior medical cost-effective susceptible necessary other acceptable timely endemic epidemic many certain unvaccinated least first last unknown unknown necessary live unknown unknown temporary maximum susceptible highest live passive immune physician-diagnosed adequate adequate local general adequate preschool-aged physiclan-diagnosed older school- measles-containing medical higher general medical other live least first earlier acceptable unvaccinated laboratory valid Self-reported parental other acceptable permanent medical allergic subsequent suseptible adverse common adverse adverse susceptible 7-12 1-2 asymptomatic rubella-containing transient 7- low susceptible temporal clinical greater higher thrombocytopenic other rubella-containing other other susceptible \ rare rare allergic severe chick fibroblast allergic Most minor anaphylactic rare uncommon severe severe allergic prior extreme serious measles- recent anaphylactic measles- other such serious egg-allergic low skin-testing predictive allergic egg- allergic prior special other pregnant due large susceptible immunocompromised general large daily least high low short alternate-day topical intra-articular high systemic component least severe severe unusual adverse variable asymptomatic symptomatic other measles-containing theoretical other clinical such other measles-containing severe asymptomatic severe immuno- severe HIV-infected total moderate ill potential such mild upper antibiotic other recent upper previous subsequent immune whole red intravenous such immune intravenous Table thrombocytopenic significant direct vaccine-induced natural greater potential greater subsequent previous previous such other measles-containing false-negative • 4-6 acceptable same mild immunosuppressive several 4-6 2°-8°C 35°-46°F due low due medical 15:5-7 1989-1990 43:451-63 272:1127-32 wild-type global 4:29-35 congenital health-care Measles-United indigenous 46:242-6 Measles-United 47:273-6 45:603-6 vaccinated sensitive clinical rapid genetic large possible molecular epidemiological wild-type wild-type critical many possible genetic several measles-specific same urine nasopharyn- possible urine possible sterile suitable isotonic such units/ml ug/ml fetal possible nasal small 3-5 much possible small sterile 2-3 cell-associated nasal epithelial possible immediate cold possible separate available whole dry dry voided urine adequate 50-100 urine 2-3 frozen at-70°C dry available available urine entire infectious capable 64:700-705 useful syncytial cytopathogenic visible Isolation-attempt 7-8 subsequent 2- possible available American ug/ml fetal 5-10 fetal viral careful single viable lower additional many free-floating light 30-35 1-1.5 clinical 7-9 least clinical speci- visible extensive necessary maximal successful immunological such fluorescent original clinical top top such small frozen dry clinical available pre-paid able re- tel:404–639-3512,404-639-3308 e-mail filtrable same cross-react various human cerebrospinal generalized ultraviolet viral • • military light regional 12-25 14-18 low-grade asymptomatic lower preschool-aged clinical postpubertal respiratory regional such infected characteristic aseptic Clinical 14-18 14-25 nonspecific low-grade common infected unilateral bilateral single salivary first asymptomatic additional nervous aseptic common inflammatory cerebrospinal higher such rare /MUMPS testicular common postpubertal postpubertal abrupt last testicular rare ovarian infrequent reversible single many temporal few sensorineural unilateral vestibular sudden compatible symptomatic rare Other less common 1-3 recent clinical particular clinical common reliable radial available routine available sensitive available detectable first few several second significant first active human asymptomatic nonclassical airborne direct infected endemic similar infectious active reportable 1983-1985 1.3-1.55 relative highest older 10-19 high single steady provisional lowest annual recent likely early 5-9 late older urban suburban serologic clinical unilateral bilateral salivary other apparent 1968-1998 1980-1998 1982-1 20-39 40- unilateral bilateral salivary other apparent -Significant inactivated short-lasting available single measles-mumps-rubella individual freeze- sterile preservative-free small noncommunicable Clinical vaccine-induced greater life-long vaccine least least first first mumps-containing early first least second first second second available first second second dose long-term available dicated first adolescent catch-up second last freeſ medical least least measles- rubella- other acceptable high second immune e physician- në • first ay commonly-used acceptable “ equivocal susceptible other peak 5- likely recognizable arbitrary necessary immune effective Most adverse such joint attributable rare adverse large-scale few lower inadequate aseptic sensorineural severe allergic prior serious measles- recent anaphylactic measles- other such serious such egg-allergic low skin-testing predictive allergic egg-allergic prior routine special theoretic immune immunosuppressive low topical immunosuppressive severe mild upper antibiotic other antibody-containing immune whole red intravenous antibody- allergic severe chick allergic remaining school-aged 2°-8°C 35°- congenital relative 142:499-507 119:187-93 5-year-old vaccine-preventable Red American little “ third separate medical distinct viral German viral 1962-65 widespread Australian early first such single other antigenic low unstable lipid respiratory regional 5-7 regional transplacental 5-7 mitotic ical • 12-23 subclinical first rare older second 1-5 14-17 low-grade upper pruritic prominent hot last several posterior cervical many integral Other soft diagnostic rare rare same last chronic rare secondary low thrombocytopenic common cerebral intrarenal last Additional late progressive main epidemic emotional disastrous early fetal common first fetal rare overall third greater uncomplicated common sole congenital such ventricular possible mental other progressive older 1964-1965 surgical/spontaneous neonatal retarded-1,800 dangerous gestational spleen clinical low high cell-mediated subclinical reliable acute rubella-specific significant positive urine cerebrospinal diagnostic viral intensive many routine valuable viral common significant possible 14-21 False-positive positive infectious positive available available preferred Enzyme-linked sensitive available easy diagnostic sensitive simple four-fold greater diagnostic recent rubella-specific primary rapid sensitive available false-positive due person-to-person airborne insect subclinical true highest contagious contagious large susceptible late 5-7 Rubella | 1966-1972-1978-1984-1990 1980-1998 1982-1997 notifiable largest annual fewer < due predominant 5-19 20-39 Most last major epidemic 1964-1965 large susceptible such religious philosophic Several recent Hispanic largest annual 5-6 due susceptible young 1990-1991 provisional clinical generalized maculopapular lymphadenopathy recent generalized probable clinical laboratory clinical clinical congenital congenital peripheral pulmonary pigmentary maculopapular 37-2C -Significant -Positive serologic congenital infection-only clinical possible compatible clinical probable probable other compatible probable eye-related single compatible HPV-77 DE-5 higher joint human other live rubella-infected aborted 25-30 human available single measles-mumps-rubella individual safe immunogenic older serologic single More vaccinated clinical least Follow-up long-term lifelong Several low detectable unknown uncommon clinical fetal vaccine-induced pregnant least least first first rubella-containing early first least second first first second second available first second second dose long-term available second first adolescent non-pregnant least rubella-containing first earlier first older medical least least measles- rubella- other acceptable high second susceptible pregnant least other live first equivocal rubella-susceptible adequate subsequent acceptable routine unvaccinated congenital acceptable pregnant unreliable many many unrecognized reliable previous reliable negative Such acceptable medical unvaccinated important pregnant detectable medical cost-effective susceptible timely prior necessary other acceptable immune effective harmful adverse such common lymphadenopathy adverse common such joint susceptible susceptible rare ~-4-1 ~~~ £-11 rare susceptible allergic severe susceptible postpubertal acute arthritis-like transient peripheral neuritic such acute 1-3 other chronic seronegative seronegative unimmunized neuropathy severe allergic prior pregnant pregnant fetal immune immunosuppressive low alternate topical immunosuppressive moderate mild upper antibiotic other antibody-containing immune whole red intravenous least antibody-containing necessary Previous human anti- immune anti-Rho immune 6-8 breast-feeding mild serious 12-15 pregnant pregnant likely pregnant next pregnant likely next • theoretical 1971-1989 other theoretical pregnant routine pregnant pregnant pregnant wild such susceptible susceptible vaccine-induced maximum theoretical low routine old 122.8-14.0 vaccine cological ºptible tible endutº etical pregnant small theoretical 2°-8°C 35°- low several high —Intensive susceptible postpubertal final susceptible young possible routine Other • susceptible immune important susceptible such two-dose adverse attributable immune congenital health-care congenital 46:350-4 Congenital 1991-1992 41:468-9,475-6 38:289-93 congenital congenital 14:573-8 vaccine-preventable Red American Primary infectious vesicular susceptible vesicular healthy other first latent regional primary 4-6 other such sensory secondary viral viral regional sensory 14-16 10-21 1-2 2-4 pruritic trunk first pruritic highest mucous clear erythematous several present several macular same successive clinical normal severe higher gastrointestinal severe progressive high extensive vesicular high prolonged primary healthy clinical other viral natural wild clinical detectable latent recurrent young skin central nervous pulmonary hepatic extramedullary cranial Most fifth cranial few systemic Post-herpetic available Post-herpetic last other severe mild self-limited common secondary bacterial skin central nervous common outpatient medical serious viral bacterial Secondary bacterial common healthy fatal nervous aseptic common good infrequent cerebral common rare maternal 1-14 15-19 20-29 unusual unknown dramatic aseptic hemorrhagic clinical healthy normal healthy higher 30- high serious high organ fulminant pneumonia high severe fetal passive maternal prior due passive low muscular cortical first congenital primary maternal first low congenital maternal virologic maternal earlier exact unknown useful necessary necessary difficult vesicular giant consistent vesicular fluorescent monoclonal sensitive reliable valid distinctive subclinical unusual necessary useful low small clinical endemic 1-2 available Available indirect indirect immune latex enzyme-linked sensitive unsuitable general diagnostic least sensitive sensitive specific available available sensitive rapid sensitive commercial useful acute significant standard single positive occur common tropical more rural insect common infected airborne direct distinct seasonal 1986-1995 highest cº-wºrthwºr early 40.000- highest lowest tropical seasonal first progressive contagious entire new contagious contagious more Secondary susceptible high Secular endemic notifiable Age-Specific less highest age-specific recent highest < 1-4 5-9-10-14 15-19 older 1990-1994 notifiable first least live attenuated viral early healthy general sequential human embryonic human small residual fetal detectable least Japanese severe healthy second least second first clinical long-lasting permanent fewer fewer many maculopapular Most 7-10 prior necessary reliable susceptible reliable susceptible severe safe effective healthy same measles-mumps- separate separate same least separate separate other other reliable immune acceptable physician necessary reliable uncertain susceptible such clinical susceptible • current susceptible immune effective Susceptible severe young Military severe illness susceptible single least healthy detectable single older first second first reliable personal reliable susceptible reliable immune likely effective susceptible desirable higher highest likely susceptible high such young institutional correctional military susceptible international susceptible high serious susceptible reliable likely effective necessary seropositive second full possible detectable unlikely 5-6 anamnestic present susceptible negative susceptible low susceptible potential vaccine-associated high serious such Post-exposure few post-exposure current additional available unvaccinated susceptible protective unknown susceptible susceptible effective necessary low vesicular uncommon wild higher severe common adverse such clinical local second local mild self-limited varicella-like second varicella-like second Most maculopapular live similar wild fewer 4-5 wild mild post-herpetic similar other severe allergic due immune immunosuppressive low alternate topical available special certain acute lymphoblastic further asymptomatic symptomatic human asymptomatic inadvertent HIV-infected clinical pregnant unknown wild small lower insert American maternal-fetal pregnant 1-800-986-8999 severe ill potential such such upper antibiotic other active 1-800-986-8999 susceptible dry antibody-containing immune whole red intravenous unknown potential least antibody-containing such seronegative healthy potential susceptible fewer secondary secondary clinical symptomatic other secondary wild several asymptomatic high such fragile frozen average frost-free last 5-10 low acceptable unsealed uninsulated small dormitory-style capable preservative other anti-viral short separate 1-800- 1-800-982-7482 short 1-800-982-7482 possible central off- difficult more higher-than-recommended available such off-site off-site high- dry pregnant human high available clinical susceptible negative greater general expensive temporary susceptible high significant continuous same 2- 4-bed direct immune neoplastic immunosuppressive less gram adequate maternal immune such susceptible congenital possible longer detailed Susceptible significant direct maternal hospitalized entire synthetic non-pregnant human available early healthy beneficial new cutaneous systemic cutaneous pulmonary short viral-mediated healthy sufficient normal more severe secondary cutaneous pulmonary short intravenous possible preschool- low protective live Varicella-related 46:409- Varicella-related 47:365-8 routine 271:375-81 vaccine-preventable Red American military infectious long- definitive other non-B common primary hygienic passive immune short-term long widespread susceptible eradicate natural several nonhuman stable stable low moderate natural low high 15-50 specific clinical asymptomatic symptomatic fecal-oral 10-12 present present several less common fecal-oral present acute clinical indistinguishable other acute viral abrupt abdominal last longer 10-15 symptomatic asymptomatic older symptomatic fulminant higher older substantial medical ill direct indirect pediatric annual detectable anti-HAV early convalescent anti-HAV present total anti-HAV anti-HAV anti-HAV total anti-HAV positive anti-HAV past available total detectable 5-10 detectable lifelong such viral helpful common molecular supportive natural animal chronic fecal-oral person-to-person present rare treated appreciable seasonal likely minimal sexual recent international waterborne Person- other asymptomatic international occupational fulminant solvent-detergent-treated noteworthy critical foodborne nosocomial rare neonatal intensive-care fecal developmental high fewer sporadic common common work-related available large last high reportable distinct largest under-reporting asymptomatic anti-HAV general 1966-1998 such high-rate intermediate-rate last several substantial high few well-defined certain religious intermediate-rate young regular several specific larger asymptomatic substantial older community-wide 20-29 40-49 highest old old old old Anti-HAV highest Anti-HAV better sanitary available high many community-wide major clinical other viral clinical serologic necessary clinical discrete positive anti-HAV significant anti-HAV inactivated whole available cell-culture-adapted human preservative 2- available pediatric protective single effective clinical clinical high clinical high long-term available 5-6 kinetic protective Other cellular long-term unknown whole seropositive seropositive seropositive critical appropriate old substantial national successive interim intermediate high available pediatric dose 6-12 second single dose 6-12 dose 6-12 6-12 6-12 initial subsequent initial * 6-12 available pediatric 2- pediatric dose 6-12 first deltoid needle 6-12 6-12 initial subsequent initial different available same preferable originally-used available acceptable first unknown pediatric adverse same other older high first second necessary older high Such certain religious Other high chronic recommended local older other chronic occupational occupational A-infected other due occupational solid routine local past such negative low effective extensive geographic high older certain certain high available total serologic high low anti- diagnostic local mild self-limited systemic low serious adverse brachial common adverse similar serious preservative 2-phenoxyethanol severe theoretical low • uncommon serious severe acute Post-Exposure human negative human serial Serious adverse effective clinical large single possible more close sexual certain common-source HAV-infected high least injected live least Table more measle- mumps- rubella-containing live reportable important specific geographic other viral non-B necessary viral public responsible such health-care other fecal-oral active passive 1996- health-care high 600-603 frozen 46:288-295 similar infectious separate early specific serologic first human early first complete serologic natural effective 5th human yellow Australian mid-1960s least million-carrier-worldwide chronic hepatocellular human small double-shelled numerous antigenic double-stranded infectious environmental least chronic primary hepatocellular common chronic chronic second human die chronic Several well-defined antigen-antibody hepatitis-associated antigenic subviral 22-nm spherical variable infectious complete infectious present complete great detectable conventional soluble high high recent detectable low clinical indistinguishable other acute viral average Clinical asymptomatic asymptomatic prodromal initial insidious quadrant abdominal icteric variable gray hepatic common other Most acute complete anti-HBs specific least asymptomatic acute complete serious due chronic chronic chronic many chronic Responsible chronic asymptomatic capable most HBV-related chronic hepatocellular active chronic early higher ºffin-Hºmo-rºma clinical clinical definitive early sensitive infectious chronic serologic acute anti-HBc recent detectable best serologic negative positive single useful infective higher protective anti-HBs positive appropriate milli- protective specific effective chronic successful other infective other universal other insect 1-2 parenteral HBs.Ag-positive highest serous lower other such other unlikely important sexual heterosexual homosexual Fecal-oral homosexual asymptomatic percutaneous important other percutaneous other sharp medical small needle such fresh cutaneous other infective other direct mucous such hand-to-mouth hand-to-eye infective infective mucous environmental various infective other positive infected perinatal positive secondary active primary hepatocellular different global high chronic positive moderate HBs.Ag-positive low positive most early chronic greatest most asymptomatic little acute chronic high low infectious present present infected chronic positive chronic positive 1978-1998 reportable many reportable distinct different available first provisional early * homosexual |- intensive clinical serologic |- infected tº-nºn-county additional acute perinatal chronic common sexual heterosexual homosexual uncommon general certain lifestyle lsº º- highest frequent chronic high 70-85 10-20 35-30 illicit parenteral 60-80 active 35-80 3-10 20-80 3-6 30-60 1-8 10-80 1-2 15-30 10-25 multiple 5-20 infrequent 3-10 first-time 3-5 available less optimal apparent several high large major infected active effective public private due rapid high-risk low initial low High-Risk difficult likely preventive high-risk low initial low Australian plasma-derived comprehensive pregnant perinatal certain high plasma-derived human safe effective unbased live other blood-borne human first recombinant second similar common recombinant yeast-derived final infectious viral complete available pediatric table different interchangeable table intramuscular healthy adequate age-specific 3- protective effective clinical complete normal protective high necessary other certain special other Usual positive intact > anamnestic anti-HBs 1-2 1-2 anterolateral Available vaccine-induced intact significant clinical significant anamnestic anti-HBs significant normal immune routine additional available annual pediatric intramuscular second third first first highest last least preferable 2-month other good appropriate difficult third least second first least third necessary longer minimum HBs.Ag-positive low least full same pediatric equivalent individual separate uncommon individual 12-15 younger potential 0-1-6 second least first least Low positive age-appropriate local young new adolescent highest flexible possible Asian active • 11-19 usual third dose 4-6 minimum first minimum second third first third less less minimum older pediatric usual third dose 4-6 minimum first minimum second third first third less minimum increased sexual other multiple sexual high-risk susceptible possible homosexual other large effective susceptible percutaneous public blood-contaminated such highest other Other special behavioral medical high-risk other Intravenous certain certain such Alaskan endemic such important susceptible susceptible high unaccompanied high positive susceptible close local sexual local common medical common high certain such high specific casual little special such medical severe potential immune cost-effective high such male cost-effective low such routine such suboptimal such necessary 1-2 definitive HBs.Ag-positive 3-9 third present anti-HBs present new comprehensive new sharp catch-up necessary significant routine high most additional additional additional such public direct primary additional additional additional first second three- HBs.Ag-positive second usual 6-month 4-month accelerated second positive HBs.Ag-negative susceptible probable parenteral HBs.Ag-positive same other high chronic effective chronic effective same different available first second third 1-2 first third oral diphtheria- few available chronic HbsAg-positive same other inadvertant positive mucous available first different 1-2 recutaneous positive negative unknown non- unknown adequate positive anti-HBs adequate adequate anti-HBs sexual single last sexual last sexual sexual high-risk positive second primary higher old other identifiable such sexual common adverse systemic such Low-grade systemic adverse serious allergic prior Such allergic rare moderate such upper available pregnant severe chronic pregnant eligible such suboptimal 2°- frozen high anti-HBs anti-HBs passive percutaneous mucous sexual less old primary systemic allergic previous severe acute high-risk low low valid current unavailable new American pregnant young early unavailable positive sexual comprehensive universal health-care American high universal human other health-care 377-82,87-8 immune public intradermal 1990-1991 40:569-72 44:574-5 vaccine-preventable Red American epidemic first world-wide epidemic least 20th “ Spanish inactivated protective single-stranded nuclear other such infectious viral least least 1918-1919 illness new • same 1957-1967 late dominant stable less antigenic immunologic human subclinical epidemic due sequential specific interpandemic irregular major antigenic protective new major due genetic last major antigenic minor major similar 1997-1998 distant last 1997-1998 different 1997-1998 much 1997-1998 1998-1999 1998-1999 antigenic major 1889-1891 1918-1920 1957- 1968-1969 pandemic single high greater 1918-1919 large severe fatal large Secondary tertiary 1-2 lower major high respiratory high early respiratory epithelial immunologic general classic clinical subsequent demonstrable • respiratory 5-10 1-5 nonproductive • primary -secondary bacterial excess older abrupt nonproductive 101°-102°F tracheal epithelial runny substernal last more such influenza rapid several most secondary bacterial influenza viral uncommon due Other chronic other chronic pulmonary cardiopulmonary other chronic antigenic excess influenza-associated older major 2- 5-fold severe influenza 1918-1919 least characteristic clinical amniotic certain viral additional local individual significant influenza convalescent 10-21 human specific least 4-fold rapid diagnostic available clinic antiviral epidemiological clinical compliment airborne 1-2 4-5 aerosolized important direct tropical 1-2 4-5 clear more excess different more excess several recent high case- high “ high-risk high-risk medical 5-fold major primary underlying due we- due epidemic influenza previous 5-year epidemic due consecutive available inactivated available Whole- prepared zonal split-virus illness dose-roºst prepared organic fewer adverse spatial viral useful prohibitive live available next few interpandemic recent effective practical • effective prior immunologic effective effective effective healthy young similar effective effective clinical effective elderly effective effective /NFLUENZA early effective more routine accessible undertaken most influenza high-risk group-United 6-35 previous older least lower febrile split-virus purified- surface-antigen split- whole-virus similar Other such intradermal subcutaneous topical older chronic • long-term Other influenza long-term pregnant chronic many chronic influenza • such chronic such congestive renal metabolic such limited serious medical recent ^ influenza-related more • second third higher nonprenant nonpregnant pregnant comparable nonpregnant high-risk medical nonpregnant high-risk least pregnant high-risk medical high-risk long-term high-risk likely elderly annual long-term high-risk other outpatient high-risk high-risk Many protective low protective immune transient viral other such pneumococcal other similar clinical serious protective many essential institutional routine foreign previous high-risk current available clinical many HIV-infected essential uncommon common adverse soreness transient Local Non-specific systemic previous viral 6-12 last 1-2 Recent systemic common immediate such allergic likely residual current small severe appropriate occupational other allergic similar medical influenza potential most intradermal indicate local delayed-type subsequent other small difficult rare such annual less true adverse lower severe older medical general low greater greater prudent previous most high severe influenza adverse clinical attributable severe previous allergic moderate severe systematic automatic adverse coolant influenza few 2'-8 35°-46°F higher high-risk epidemic- influenza-related older older previous lower black Hispanic non-Hispanic white high previous least medical previous less high-risk effective high-risk other residential long-term Acute-care high-risk hospital outpatient high-risk necessary other influenza prior appropriate high-risk effective effective high-risk poor severe antiviral specific specific antiviral effective fewer effective adjunct late unvaccinated high-risk poor high influenza renal other systemic due current more antiviral general referral likely susceptible high-risk medical antiviral high-risk protective unimmunized Other elective uncomplicated new necessary influenza-related economic rapid preventive unvaccinated high-risk weekly regional less nationwide weekly nasopharyngeal 1987-1988 culture-confirmed detailed other early new rapid preventive influenza-related economic epidemic s-90 nursing-home 45:1100-5 health-care 1997-1998 1998-1999 47:280-4 1988-1992 42:601-4 47:797-802 performance-based elderly elderly asthmatic 106:931-3 healthy 333:889-93 Red American wide-spread more other preventable pneumococcal other pneumococcal bacterial effective pneumococcal many antibiotic late pneumococcal first pneumococcal lancet-shaped gram- positive facultative anaerobic short pathogenic experimental other More • Gram-positive • important type-specific protective upper normal chest community-acquired hospital-acquired higher elderly primary antigenic least type- specific protective pneumococcal other additional common normal asymptomatic upper military many natural major clinical invasive pneumococcal pulmonary common clinical invasive pneumococcal pneumococcal short single uncommon Other common pleuritic rapid poor rapid pneumococcal community- hospital-acquired common bacterial much higher elderly pneumococcal pleural pneumococcal pneumococcal overall high elderly fulminant clinical pneumococcal pneumococcal pneumococcal clinical similar other bacterial nuchal cranial pneumococcal high elderly common pneumococcal definitive other sterile available capsular lancet-shaped suggestive difficult normal pneumococcal white epithelial 100-power gram-positive higher elderly young elderly bacterial elderly common capsular rapid clinical spinal pneumococcal positive large rapid specific diagnostic pneumococcal various spinal pleural highest spinal similar sensitive spinal rapid useful poor other resistant specific pneumococcal infective effective antimicrobial human asymptomatic direct person-to-person upper pneumococcal responsible such upper such pneumococcal high common early prevalent pneumococcal unknown reportable population-based invasive pneumococcal 2-2-4 overall pneumococcal 15-19 older o 19-24 ºnto-º-º-º-º-º- 25-8 0-8 7-12 13-18 uncommon invasive high 14-valent • 23-valent younger high recent highest 13-18 pneumococcal pneumococcal highest medical young older high-risk bacteremic older pneumococcal sporadic pulmonary Secondary pneumococcal common bacterial pneumococcal such invasive high pneumococcal pneumococcal capsular different pneumococcal 23-valent 14- pneumococcal pneumococcal bacteremic pneumococcal cross- several capsular additional single healthy pneumococcal poor significant pneumococcal significant healthy young elderly chronic lower least healthy certain underlying various clinical effective invasive effective nonbacteremic pneumococcal effective pneumococcal significant underlying effective normal such high severe pneumococcal significant vaccine-type non-vaccine-type older normal chronic cardiovascular pulmonary cerebrospinal pneumococcal effective capsular bacteremic pneumococcal Cross-react additional normal immune chronic chronic renal nephrotic splenic pneumococcal splenic surgical chronic renal nephrotic such organ asymptomatic symptomatic old older long-term high serious pneumococcal nephrotic asymptomatic symptomatic healthy special social pneumococcal such certain Native American elective least two-week other immunosuppressive complete uncertain unknown pneumococcal 5-10 certain higher whº ent rid available pneumococcal substantial improved multiple pneumococcal routine 23-valent older highest serious pneumococcal likely rapid pneumococcal high-risk previous highest severe pneumococcal less highest functional anatomic sickle multiple chronic renal nephrotic other organ immunosuppressive long-term older second more first Adverse common adverse pneumococcal local less systemic such uncommon severe systemic adverse rare first pneumococcal clinical immunologic serious pneumococcal first dose children-revaccinate renal adverse severe high-risk black hispanic severe pneumococcal 3-5 serious allergic pneumococcal Such allergic rare severe such upper pneumococcal healthy pregnant high pneumococcal coolant pneumococcal few 2°-8°C 35°-46°F pneumococcal same different pneumococcal highest pneumococcal random-digit-dialed non- older older pneumococcal black hispanic lower white high-risk other serious pneumococcal high pneumococcal subsequent high significant pneumococcal pneumococcal efficacious invasive pneumococcal efficacious pneumococcal current effective highest invasive pneumococcal young several conjugate pneumococcal invasive pneumococcal young late clinical 7-valent pneumococcal effective pneumococcal young pneumococcal available Pneumococcal current 270:1826-31 Pneumococcal present 1506-8 pneumococcal 47:797-902 272:1133-7 pneumococcal 281:243-8 protective pneumococcal Red American invasive pneumococcal pneumococcal 174:752-9 public safe effective vaccine-preventable public true adverse adverse current vaccine-preventable pre-vaccine vaccine adverse critical epidemic several other similar willing different such Vaccine-Preventable high vaccine-preventable visible public dynamic necessary global due due routine prior actual global live oral true unrelated public full new possible higher other medical pharmaceutical healthy healthy healthy lower sick possible rare adverse acceptable other pharmaceutical large local medical public clinical fewer Higher primum -Moral public clinical healthy Lower rare rare costly difficult likely definitive higher narrow many other effective few alternative oral best wide many low public attributable critical adverse risk-benefit erroneous attributable disastrous many public safe several adverse true false unrelated scientific former first possible incomplete severe adverse biologic adverse 1991-1994 Pre-Licensure placebo-controlled -asy many population-based epidemiologic persuasive few experimental relative epidemiologic Such costly difficult less familiar infectious other specific appropriate negative other pharmaceutical undergo extensive sequentially-phased human clinical important successive common unvaccinated medical common local systemic rare critical passive epidemiologic large-linked specific adverse potential specific timely Fundamental public critical appropriate safe formal spontaneous vaccine relative low adverse same other adverse national infectious national public local adverse pre-organized difficult unvaccinated Spontaneous Co-project -Detect unknown rare potential certain adverse national significant adverse narrative adverse open adverse medical general internal adverse demographic medical past adverse other 1-800-822-7967 “ serious additional on-line analytical respective personal available serious serious adverse previously-unknown evaluative common rare local recent adverse due intrinsic individual vaccine-associated paralytic due technical due rare potential clinical serious Such such clinical natural adverse previous general alternative particular specific adverse next attributable critical adverse particular coincidental adverse unique diagnostic viral adverse genetic unique clinical acute classical oral wild unlikely unvaccinated adverse few such “ other relative available Large-Linked potential passive Such informative costly time-consuming single passive adverse large computerized medical such single-provider such vaccine adverse under- economical rapid medical various high difficult preventable widespread evident little personal other more “ visible personal Other social timely inaccurate controversy-seeking alternative inaccurate active Large-Linked scientific rigorous causal-Vaccine attributable -Individual professional important public environmental public alternative average vaccine-injured voluntary acceptable involuntary educational many other such private public other such many various good preventable countless public decision-making democratic other medical important many public many tragic philosophical medical religious specific delicate societal individual scientific clinical first objective open new unscientific equal greater such scientific difficult scientific prominent few rare critical medical scientific preventable real critical certain certain small severe permanent adverse 12:542-50 methodological vaccine 112:10-20 Adverse large-linked independent synergistic Antibody-Live Vaccine-Preventable 1950-1998 Vaccine-Preventable recommended minimum 4-6 14-16 American routine other detailed * HBs.Ag-negative least least least HBs.Ag-positive separate unknownshould receive positive possible Special moderate high whole-cell acceptable early unlikely 15-18 last Subsequent clinical lower immune primary oral first sequential 12-18 4-6 acceptable acceptable special such late unacceptable imminent polio-endemic due new other first minimum older first 4-6 second 11-12 old susceptible reliable susceptible older least sº- late first second third necessary fourth fourth necessary third dose fourth last first 12-15 appropriate specific acellular acceptable first acceptable special such late unacceptable imminent polio-endemic fourth third first 7-11 third dose second first subsequent vorious live internotionol units/10kg 20-40 negligible Whole 80-100 300-400 entire interval odditional immune thrombocytopenic initial dose primary acceptable current accelerated total seventh least previous 'Sequential all-OPV unvaccinated < available least third fourth fourth young first 12-15 additional local other measles-containing least final Table Birth-10 11-19 three- dose HBSAg-positive due due severe gastrointestinal unstable neurologic other severe antibody-containing due severe antibody-containing previous unstable previous severe inconsolable severe other minimum mild previous same acceptable Anaphylactic prior acellular 15-18m 4-6 least severe minor early early previous present give other separate Previous serious prior severe minor other separate prior severe minor previous other separate 12-18m 4-6yrs early least severe minor “ all-IPV other close all-IPV acceptable sequential immediate 6-18m 4-6yrs |- minimal early anti-cancer high-dose complete best medical certain supplemental other separate other previous severe acute minor Susceptible other live 4-8wks same other separate previous due high-dose immunosuppressive pneumococcal many at-risk full recent latest other minimum mild other live same possible next 12-15m 4-6 severe minor minimum past 12- least minimum other live previous same high-dose other separate 1-30 prior severe minor early previous previous other separate previous 12-15m 12-15m 12-14m |Give 3-11 give 21-2m 12-15m 12-14m previous component 3-dose severe minor 0-2m 1-4m 6-18m older other possible positive hep-B 1-2m unknown 1-2 0-19 old HBs.Ag-positive 0-19 old additional first Engerix-B different endemic complete other separate two-sided * * r- welcome 651/647-9009 651/647-913 recent ummary usual simultaneous older anaphylactic medical such renal optimal chronic separate severe pregnant medical anaphylactic other chronic one-time pulmonary anatomic functional separate special severe acute social certain American Indian highest high immunocompromised fatal pneumococcal chronic renal nephrotic immunosuppressive previous high-risk anaphylactic HBs.Ag-positive injectable more separate renal severe certain public long-term correctional certain international national least previous endemic HBs.Ag-positive appropriate susceptible anaphylactic dose separate severe experimental medical private cost-effective likely effective younger certain high specific full complete 800/232- recent severe mild acute two-sided appropriate immuni- national < sure current usual simultaneous dose primary anaphylactic sure primary severe separate primary 6-12 anaphylactic least early dose skin separate such other high educational same international immunocompromised due acceptable immunosuppressive least dose immune immune desirable severe acute 4-6 susceptible anaphylactic susceptible close serious dose susceptible 4-8 due high young institutional such high immunosuppressive same correctional non-pregnant international least reliable such parental severe reliable serologic effective negative uncertain immune older primary unique separate wild-type likely endemic severe mild acute welcome * clear sick serious neurological other | other x-ray immune pregnant next important personal sure clinic junior high clinic clear serious other other x-ray immune possible pregnant pregnant next important personal clinic sure clinic extra serious many due ex- swollen hot red clean accurate such higher older tem- lower con- few much fever-reducing weight 1-3 4-11 12-23 6-11 12-17 18-23 24-35 36-47 dropperful dropperful droppersful QT-in- QTHºm- “ chewable 65|-647-9009 1950-1998 paralytic paralytic reportable other other notifiable Many retrospective late paralytic medical Reportable 1950-1965 provisional respective Vaccine-Preventable paralytic provisional 1962-1997 4–3–1-3 4-3-1-3 | measles-containing 2-year-old 19-35-month-old more measles-containing more measles- more Most current urban 19-35 547-54. individual urban more measles-containing first more more least more more Community-Based 1992-1993 Community-Based Other comprehensive ultimate best primary Overall primary intensive many vulnerable preschool-aged due clinic present user-friendly family-centered sensitive comprehensive rapid efficient consumer-oriented recent measles-related other vaccine-preventable pediatric public private desirable possible own necessary useful additional available unnecessary available free minimal clinical general true eligible accurate complete other adverse semi-annual up-to-date retrievable medical patient-oriented community-based current dvailable responsive large urban public available daily smaller rural many other same primary Ready unnecessary public private available walk-in routine new available other comprehensive such primary appoint- physical reliable guardian assess- general guardian potential public dependent individual referral primary free free private reasonable Affordable greatest private consolidated federal eligible regular particular other general sensitive own full appropriate educational suitable specific acceptable possible adverse prior federal own alternative other public private current available appropriate satisfactory medical day- night- adverse true true true true more detailed American eligible simultaneous safe effective simultaneous such automatic routine complete personal official personal new previous prior former regular manual separate retrievable inactive separate primary other other other such dental such adverse legal such significant available 1-800-822-7967 adverse medical possible 300aa-25 overdue manual additional intensive high local public private pre- school-aged up-to-date second simultaneous such ongoing up-to-date retrievable medical appropriate possible adverse Such necessary medical medical familiar patient-oriented community- necessary more user-friendly community-based high active Such community-based public local high high vaccine-preventable highest possible trained appropriate other administer create legal necessary current current other such national complete detailed local injectable Low-grade moderate severe timicrobial urrent antimicrobial same normal full-term infectious other such previous previous attributable identifiable hyporesponsive adverse personal inconsolable prior specific individual foreign neurologic individual certain pregnant prudent theoretical immediate personal additional further own solid congenital antimicrobial long-term immunosuppressive positive hematological solid long-term severe severe thrombocytopenic same 4-6 positive 4-6 natural greater potential greater close temporal subsequent anaphylactic measles- other anaphylactic measles- mumps-containing low allergic allergic hematological solid other congenital long-term immunosuppressive same safe effective healthy same separate separate least red such seronegative other menu-driven relational practice-based many other special current extensive individual in-depth available vaccine-specific diagnostic last various specific least new new primary previous own single same same same Non-Simultaneous last special eligible minimum Late office-based Late Drop-Off sharp Up-To-Date flow second many more flow “ age-specific same graphic age-specific specific adequate specific specific important top 24-month-old poor Other early possible low high eligible Non-Simultaneous flow previous simultaneous particular earliest whole simultaneous simultaneous useful several due several same simultaneous negative next same last many high good false high false effective likely due general Last last high eligible many Good other “ high high more main many many good small high non- many local first possible new high primary many false good severe specific particular simultaneous aggressive due other physical limited Client-flow psychological general responsive additional direct personal due non-simultaneous last invalid minor last last invalid important additional standard last last latest apparent newborn primary Late office-based first sufficient GOOD Last Last Eligible Additional LATE 24-35 “ 24-35 Drop-Off 24-35 Last definitive evidence-based e-mail pre-school other Windows-based assessment manual little large more and/or vaccine-preventable such 404-639-8222 404-639–8392 mixed 404–639-8225 diligent low public private great free e-mail @ Self-Assessment sure self- specific full younger younger Many pedia- mild acute many self-assessment younger appropriate current self-assessment simple good first successful nation-complete least old younger « Cººl- direr- 31faignt- easy useful younger many important compli- many follow-up other potential new immu- practical immu- self-assessment consecutive younger next individual next few con- useful strength- under- individual broad medical public desirable current immuniza- public private useful necessary desirable available unnecessary available free minimal clinical general specific true eligible complete other adverse due semi-annual retrievable medical community-based current acceptable 6-18 HBs.Ag-positive immune vac- separate 1-2 unknown whole-cell acceptable fourth early third unlikely 15-18 complet- primary poliovirus oral acceptable 12-18 12-18 6-18 immunocompromised second least first ‘ ble reliable 11-12 year-old ſwinimum acceptable first high primary least previous mn- —H·- young first additional adminis- kºcal other least leastbusy screen younger multiple par- eligible old younger older closest younger Example 9-month-old 6-month recommended up-to-date up-to-date sufficient last true physician appropriate medical up-to-date Up-to-Date up-to-date all|mmuniza- up-to-date indicated up-to-date opposite follow-up rectal right old nurse nurse up-to-date old nurse old sufficient last nurse acute younger closest younger 9-month-old recom- recom- -º-º- up-to-date Up-to- henstop |- º- 35-2-1 simum due unable ſea- up-to-date available small definitive overall up-to-a-to-vaccine-by-mao |- up-to-date up-to-date up-to-date up-to-date up-to-date summary Total actual up-to-date valid up-to-date national full necessary Total up-to-date up-to-date multiple up-to-date unable available Other common up-to-date up-to-date same 4-6 up-to up-to-date certain Other up-to-date satisfactory certain less up-to-date possible possible Next few sick valuable assess- good desirable great self-assessment own useful entire interval up-to-date up-to-date minimum interval follow-up necessary simultaneous applicable 12-15 current next unable lf local free sure on-time unavailable adequate age-appropriate de- scribe vaccine-preventable such cultural acute available appropriate chronological specific up-to-date vaccine-preventable true present alsº 12×I-I-I-T-I-T- cerebral anaphylactic anaphylactic low-grade anaphylactic araphylactic anaphylactic ++- nonanaphylactic * —t- previous ºws-Nº- previous kcal mild-to-moderate current previous dose +- r- previous recent infectious contagious Simultaneous r-T-r-T- F-T— low-grade mild i–1–1 —l-1-1- moderate-o-tºwere asymptomatic symptomatic positive intravenous re- simulaneous unvaccinated mild low-grade low-grade moderale-to-severe chronic |-l |- centalmerous general unresponsiveness ſocal few + +- | long-term immunosuppressive congental anaphylactic gelatin-containing personal out- foreign previous moderate severe asymptomatic stic severe unavoidable different 3-6 first vaccina- foreign normal red ſº whole humoral thrombocytopenic thrombocytopenic least red such seronegative great chronic ill- vac- individual other acute lymphoblastic stable neurologia well-controlled appropriate usual same normal full-term antigen-positive first contraind- primary toxoid clean minor passive for- personal additional further theoretical multiple live same suboptimal current exac- natural greater potential greater pior prudent subsequent same 4-6 admin- positive 4-8 other same sub- stantial 5-10 same More -tº- menu-driven relational in-depth sta- critical antigen-specific immºnzº- 404-639-8392 more 202-463-0550 202–463-0555 medical self-study self-study vacci- medical available more 800–789-8737 comprehensive vaccine-preventable other more latest immlu- single quick other desirable available 301-650-0373 closest younger 9-month-old vaccine cee-Fillin immu- recom- up-to- * ºlº- º- us-ºn similtaneous due f up-to-date ble [ unable up-to-date available [ rea- Other Community-Based 1992-1993 community-based public clinic resi- Clinic-based monthly reminder-recall door-to-door mobile vaccina- temporary on-site free lo- cal vaccina- af- clinic-based comple- clin- net +15 resi- dence-based age-appropriate significant +3 Reminder-recall commu- nity-based in- sta- significant residence-based com- munity-based community-based urban poor com- public most urban public 1992.com- public exist- second second highest in- certain African American worse com- munity-based vac- un- community-based or- public first community-based vac- — comple- exist- health-related several bile private gov- local public local public public African ethnic lower socioeconomic com- public predomi- African American private predomi- Hispanic interven- estab- underserved same racial/ethnic popu- in- commu- distinct vaccina- identified vac- tele- necessary door-to-door undervac- sensitive promotional lit- com- munity-based fol- weekly temporary on-site free vaccina- or- other organiza- such local broad impro- opportunistic invariant ob- at-risk many possible common community- Table in- significant unvaccinated significant simulta- neous ei- complete rank-ordered improve- noninter- significant total commu- younger old docu- total younger es- overall exclud- other many reluctant unknown final sur- community-based organi- profes- sional ses- public private land- unable reliable many vacant younger difficult denomi- con- final af- younger least subsequent available younger avail- able community-based total younger average younger total num- ascertainment be- pub- lic non- narrower 21-23 public clinic Age-appro- stan- teta- oral “ 4-3-1 2-tailed total overall age-appropriate median identical in- public sub- stantial present sub- Table Age-specific small youngest sug- low first se- median public different age-appropriate median attributable progressive vacci- age-specific cover- 7- 15- average ==- intenemian stantial significant fable children.3 1992-1993 age-appropriateº ublic łºchildren:24-59 significant true vaccina- these- median public different im- public previous consistent in- greater dif- significant overall Table nonsignifi- cant 8-percentage younger familiar com- munity-based friendly professional vaccina- usual temporary usual public private other more — first community-based or- clinic-based reminder-recall broad spec- residence-based same particular clinic low costly difficult residence-based sur- greater serv- same other undervaccinated pro- door- undervaccinated cover- independent public general large-scale im- public dur- interven- public usual consistent indepen- public population-based consistent public missed simultaneous in- internal com- nonsignificant community-based re- minder-recall instrumental interven- 15-percentage cov- consistent ef- provider-based similar such monthly unvaccinated certain cho- pro- clin- clin- other significant other ul- residence-based vac- popu- independent serv- community-based com- refractory operational com- munity-based extensive prior experi- long-standing tar- small more 6-month 12-month interven- ad- 8-percentage vac- community-based in- plausible intermediary “ hard- in- individual interven- residence-based previous immu- collective provider-based effective multiple re- favor- able provid- important residence-based other vaccina- many con- eligible high- initial available subsequent initial door-to-door high provider-based unvaccinated chil- time-consuming ardous interven- familiar community-based friendly professional usual public Resis- com- prehensive usual other ef- single regular consistent random community-based organiza- previous fea- im- dem- likely at- tributable rigorous Other popula- available ascer- higher representative general con- character- identi- clinic-based identical 4- 3-1 larger community-based or- few inter- ef- many individual community-based com- public high-risk urban public previous inner-city community-based or- age-appropriate vaccina- other public community-based evalu- measurable public evalu- in- public other helpful tional — public 1988-1994 1997:277:631-635 vital 1996.98:1007-1019 international hu- high-risk com- RR-6 high 1993:83:862-867 inner-City African-American 1995.96.295-301. critical 1996:97:735-737 inner 1994:94:53-58. well-child 1994:272:1111-1115. follow-up 1991:7:24-28. evalu- 1984:17313-325. mailed high Abstract 1996.86:1551-1556. en- different 1995.274:312-316 im- inner Abstract Community-based strat- primary :14-20 Community-Based provid- community-based pub- lic ” Community-based or- key con- public scientific appropriate educational referral in- dividual Community-based public public initia- * intensive community-based educa- clinic-based reminder-recall community-based broad young clinic-based monthly first comparative clinic-based community-based vaccina- educa- tional community-based improvisational opportunistic tar- specific appro- particular educa- sensitive weekly temporary on-site sta- free pro- impressive organi- such limited per- com- munity-based rela- tive significant clinic African pri- community-based greater clinic-based reminder- effective immuniza- develop- extensive clinic-based ad- timely fo- clinic-based parental differential effec- parental positive specific target- narrow con- community-based chil- distinct school-bound broad or- educational effective particular clinic-based primary rela- commu- difficult primary important time-consuming community-based out- referral follow-up appoint- ap- out- or- temporary primary difficult public private or- follow-up dilut- out- same possible public ob- public community-wide low- clinic much orga- mobile entire certain such public specific re- specific little community-based in- interven- greater immuniza- public African American different inherent community-based in- ineffective many inter- effective counterproductive community-based ef- fective vac- clinic-based population- dual in- population-based able clinic costly such present large sufficient younger inter- addi- population-based subject available legible fewer younger ben- comparable sim- able other clinic-based public other particular other clinical other standard clinical hard community-wide in- in- precise different complex effec- tive reminder-recall method- ological separate clinic-based community-based more sen- sitive community-based community-based academic medical public technical community-based effec- Annual community- rural Annual nual vical ral bicultural panic 1997:29:254-257 high ap- inter- community-based inner-city cover- 1998:133:327-332 Community-based human 1981:5:79-86 work- integral 85:1055-1058 da- Community-based immu- 14-20 272:1133-7 patient 1973-1997 many vaccine-preventable pneumococcal vaccine-preventable pneumococcal young 1985-90 safe effective available high medical previous least outpatient serious pneumococcal least previous pneumococcal 4-H appropriate health-care other health-care complete health-care high-risk influenza annual health-care high-risk other appropriate prior health-care comprehensive other higher other medical appropriate vaccine- preventable health-care third-party governmental health-care standard personal institutional public private educational motivational efficient public private national many older infectious such pneumococcal older pneumococcal certain high-risk older common serious pneumococcal other flu-related new other such most other necessary special vaccine- preventable Effective safe available Several low inadequate aware- medical public private federal major public major clinical financial public private vaccine-preventable dis- vaccine-preventable new prac- international many infec- tious ” disap- whoop- indig- enous few congenital ru- re- extraordinary attributable widespread congenital syn- able constant complete 19942.72:1133-1137 vaccine-preventable strik- fewer diedfwaccine-prevent- able compari- influ- pneumococcal hepa- many child- vaccine-preventable young major such Vaccine-preventable main important costly American several ad- much heavier ex- per- general vaccine-preventable signifi- cant effi- several immuniza- selective universal different different individual larger child- child- communi- few private ne- private in- expensive free most full public avail- responsible high best diffi- same new pneumococcal vac- many new ini- American fectious next influenza cost- Table vaccine-Preventable paralytic 1964-1966 available provisional vaccine-associated reportable reportable Table potential additional annual |Variable * variable different Japanese yellow applicable adultim- strong cost-effective un- prevented less first general high-risk immu- pneumococcal new under- able clinical Several good organiza- vac- specificqe- successful regular public se- vaccine-preventable essen- elderly severe pneumococcal young sexual ac- Many un- clinical public immuniza- admin- helpful older educa- tional other wide- spread rec- pe- riodic immu- better understand- administrative organiza- tional successful profes- prac- tical vaccine-preventabledis- ben- easy vac- recom- educational espe- announce- popu- efficacious effective local public federalcon- epidemiol- vaccine-preventable pro- * 18-24 25-64 high-risk medical special occu- environmental foreign diphthena second postsecondary educational international able Such vaccina- several mis- vac- vaccine-preventable due vac- high Most ad- wide principal general spe- profession- administrative such such single respon- dif- devel- workable Such common other federal vaccine local com- provid- administra- tive organizational stan- regular evalu- financial federal local pneu- mococcal local unpublished pneumococcal vacci- elderly reim- end- renal influenza reim- pneumococ- cal pneu- mococcal pro- apparent annual little ex- private adultim- organi- such nobet- tra- ditional regulatory private im- sufficient subject gov- Similar reimburse administra- moni- fiscal iden- tified technical financial other private reimburse indi- vidual cov- public effective vaccine-preventable adequate local adequate financial such national systern vaccine- adequate vaccine-preventable clinical insured national pro- immu- vaccine- preventable continu- them- capac- periodic vac- effective efficient vac- clear un- epi- important per- local vaccine-preventable ex- timely ad- current ” under- hepati- pneumococcal inexpensive rapid essential economic vac- cine-preventable immuniza- constant pro- forchildhood economic vac- es- costly pneumococcal pneumococcal little geographic great vac- other high-risk more surveil- vaccine-preventable local better recom- current future peri- potential technical regulatory financial legal political appropriate federal detailed specific high-risk condi- specific supportforpro- deliverywhere un- fol- pneumococcal older least pneumococcal influenza non- high-risk least high-risk antigen-pôsitive least work- least intravenous-drug us- homosexual bac- essential new vac- important vaccina- older immune responsive initial clinical serious costly vaccine-preventable pneumococcal effective other common elderſ tº vaccine-preventablediseasº greatest several new cold-adapted live pneumococcal acellur new newer epitope-based immunologic wº ventable other international such such former antimicrobial-resistan many co- new new direct new immunization—The cal vaccine-preventable immunocompromised de- better economic consequencesofcur- future vaccine-preventable dis- immuniza- evi- current fu- recom- greater stud- stable com- greater betweenfederal nongovernmen- tal professional associa- interna- tional 1992:3:27:1794-1800 Gen- eral recommen- Eradi- 10222-229 1980- 1992:43:451-468 congenital 1992-267.2616-26.20 univer- 1989:84779-784 in- 1987-1998 Reportable vaccine-preventable 43:57-60 1998328:1252-1258 medical set- em- sub- stantial immuni- less op- timal infectious im- optimal adverº re-e- produc- Na- im- elderly public preventable demon- 1988-1992 pub- pneumococcal elderly 1992:8:183-199 1998:109-113 * influ- enºa tional mem- public computer-generated vac- alternative 1990.268:1218-12 Pneumococcal poly- cur- 1998.270:1826-1831 1986:140:528-680 Comprehensive 1986-1902 Russian 1990- 501-508 drug-resistant pneumococcal immunization—The old lifelong life-protecting professional up-to-date sure Many pneumococcal other flushot older long-term younger medical such immune physical live pneumococcal pneumococcal older younger certain chronic individu- particular one-time least basic tetanus-diphtheria third dose second second many certain second 6-12 first third second second dose second international second professional additional international 404-332-4559 651-647-9009 serious other moderate sudden greater low possible pregnant next active untreated other such long-term oral anaphylactic inactivated contact dermatitis-type true anaphylactic moderate pregnant pregnant live local -Call 1-800-232–2522 1-800-232–0233 older high older least basic pneumococcal objective unknown 1973-1997 objective old eerious Many little tetanus-diphtheria measles-mumps-rubella pneumococcal lifelong life-protecting nurse sure sure last “ older high such many pneumococcal pneumococcal additional local special 11-12 old American good sure 651-647-9009 last updated dose e-IPVA dose vial dose vial dose vial dose vial dose vial vial dose dose dose vial dose vial dose dose vial vial single dose ml dose vial dose vial dose available 881-5600 x 672-6372 487-8751 North American 682-2666 Parke-Davis 223-0432 Swiss 533-5899 Wyeth-Lederle 572-8221 Wyeth-Ayerst 544-9871 /isd/teb/texts/drug 2°-8°C 35°-46°F direct frozen 2°-8°C 35°-46°F insulated frozen 2°-8°C 35°-46°F con- voccine Hib-Merck-ovalloble liquid one-dose good 2°-8°C 35°-46°F frozen 35°-46°F 2°-8°C 35°-46°F reconsti- 2°-8°C 35°-46°F Hib-Merck-ovailable one-dose good 2°-8°C 35°-46°F possible excessive frozen 2°-8°C 35°-46°F current insuloted frozen 2°-8°C 35°-46°F lower sterile such d needle Special clear insuloted dry warm 2°-8°C 35°-46°F such 15°-30°C 59°-86°F entire inject 10-Dose sterile needle 50-Dose dark 2°-8°C 35°-46°F Special 10-Dose needle dry frozen at-14°C lower permis- total frozen 2°-8°C 35°-46°F using—moy ropid 2°-8°C 35°-46°F permissible cumuloſive red usual dry due low possible withdraw- Special severe local insulated 2°-8°C 35°-46°F possible excessive frozen tempero- ure 2°-8°C 35°-46°F good Special Tetonus-Diphtherid 2°-8°C 35°-46°F direct frozen 2°-8°C 35°-46°F Special dry present frozen d Coreful necessory edrliest prod- other thot 1-800-9-827–4829 expensive |- typical oral stable big cold short-dated last correct specific Expensive electrical electrical electrical more Safe best small separate last Last helpful frozen frozen important present ok short longest “ important outdated sure accidental own pts-Dormitory proper pts-Dormitory small pts-Always pts-Daily excellent pts-Daily excellent pts-You least proper heavy pts-It necessary +2 pts-Correct pts- much lower right fine pts-Some liquid pts-Correct pts-Never -2 pts-A frost- free pts-correct fresh “ pts-Always pts-Avoid 18-20 14-16 few important local wº- domestic foreign generic several 12/69-present 1987-1989 live 3/70-76 German Russian 1950-1975 1963-1966 1964-1973 live inactivated Spanish acellular 1955-1988 Swedish live live 1973-present live present live 1978-present live Russian live live live 1978-present live 1978-present live Norwegian German German oral Italian oral present Russian Italian live live 1965-1969 German 1963-Present derivative salk-type 1956-1965 German human immune oral oral Italian French oral oral oral ustralia ustria uda blic ial uam uatemala uinea-Bissau ul un ud blic unisia urk urkmenistan uvalu ietnam summary Other available relevant prior isual oral own ubstantive acceptable 'ederal legal minor other good first permanent medical permanent medical legal additional applicable camera-ready available available § 300aa-25 minor legal currently-available interim final available generic current available up-to-date current public private own own local other prior Camera-ready responsible public single camera-ready private available identical camera-ready camera-ready camera-ready additional clear easy camera-ready camera-ready good enough procedural informed oral informed legal medical legal permanent medical legal legal other multi-dose several neurological legal acceptable desirable serious certain unable Spanish available other Several other available Armenian camera-ready camera-ready new single “ fax-back 1-888-232-3299 other current available .pdf camera- ready current new available own available current pneumococcal Most current available Spanish pneumococcal available other available Spanish 5-9 commercial large available vaccine-related national Other medical available greatest scientific clinical medical Canadian other medical available other non-clinical related familiar relevant false vaccine-related adverse vaccine-preventable further available valuable health-related vaccine-related such Most plus exact same subject successful valuable possible useful many other www.cdc.gov/nip/vacsafe health-related available non-profit many latest commercial drug-related clinical medical medical free one-time up-to-date several available daily Vaccine-Related common narrative possible adverse detailed clinical other specific serious adverse extensive other Vaccine-Preventable vaccine-preventable infectious comprehensive technical available vaccine-preventable possible key current scientific so-called hot adverse harmful vaccine-preventable multiple different same harmful 20892-2520 general different Possible first adverse current adverse adverse second immunologic genetic individual current adverse weekly latest available vaccine-related therapeutic other Other vaccine-related partial available weekly specific related particular short new public special well-informed Vaccine-Preventable current 542-548 vaccine 112:10-20 Clinical 1-11. federal available Other Other Japanese Programmatic 217-218 Provider-Based general local vaccine-preventable Spanish referral international 639-8828 www.cdc.gov/nip/vacsafe vaccine adverse toll-free vaccine-related bi-weekly latest 639-8548 wide-ranging local such informational current specific adverse specific disclosable such personal additional 8A-35 certain vaccine-related adverse significant adverse higher adverse adverse difficult coincidental adverse immunization-related federal Other Other vaccine-preventable preventable Other www.allkidscount.org follow-up other local federal overall available www.aap.org American young 20037-2985 allied on-going pharmaceutical 20005-2605 www.apha.org health-related general scientific annual educational 20005-4006 www.astho.org/index.html public many legislative educational scientific programmatic public www.nursingworld.org/echt American critical systematic latest related nationwide current physician appropriate vaccine-preventable pregnant Other high-risk semi-annual valuable available Infectious comprehensive general routine i .907-0878 professional medical other general mental human community-based federal local low epidemic non-Hispanic white available largest constituency-based national national community-based technical other national regional local health-related Spanish-language private public retroactive vaccine-related adverse new new final automatic appropriate new current statutory retroactive paralytic injured legal least vaccine first vaccine-related following toll-free 1-800-338-2382 further 8A-46 individual special initial special pre-existing specific vaccine legal complex medical most due unrelated civil last eligible noncompensable many Other unspecified vaccine-related vaccine-related such vaccine-related certain civil new restrictive non-compensable effective Residual further brachial encephalopathy tetanus- residual measles-containing live new automatic such additional new other Table effective permanent medical adverse longer interested real suspected adverse 1-800-822-7967 many many recent total fiscal total pre-1988 pre-1988 post-1988 post-1988 overall pre-1988 pre-1988 pre-1988 post-1988 post-1988 overall pre-1988 significant anaphylactic 2-28 applicable anaphylactic partial specific applicable || anaphylactic 5-15 less vaccine applicable applicable 7-30 applicable live non-immunodeficient applicable non-immunodeficient applicable applicable anaphylactic applicable º anaphylactic applicable unconjugated applicable applicable applicable new applicable routine severe lethal few cardiovascular Other significant clinical lower minimal spleen significant pathologic such applicable such more associated least less havingr postictal older least significant mental confusional independent intracranial clinical clinical least greater applicable painful other absent external familiar clinical significant mental high-pitched unusual inconsolable other first applicable least mºnº normal neurologic encephalopathy residual chronic secondary genetic chronic encephalopathy metabolic structural genetic metabolic structural genetic vaccine-related possible entire medical residual first 5-15 less additional distinct equal greater oral equal greater distinct convulsive 24-hour expert neurological particular residual myoclonic tonic-clonic grand complex partial continuous more Medical chronic such connective systemic systemic mixed connective degenerative infectious other direct immune metabolic neuropathic inflammatory joint chronic other peripheral ingle peripheral central spinal nervous deep severe upper upper able clinical present same opposite bilateral upper physical ctromyographic consistent attributable distinguishable peripheral other peripheral central ſºvous cranial tombocytopenic other such previous lymphoproliferative hemolytic uremic viral intravascular bacterial viral human antecedent viral clinical normal normal |ccine-strain viral vaccine-specific monoclonal vaccine-strain sufficient specific vaccine-strain arly-onset invasive sterile clinical invasive radiographic positive invasive bacterial -V Toll-free 1-800-822-7967 Last Responsible Other different adverse appropriate permanent diagnostic other office/hospital clinic/hospital Other Other ſunknown Pre-existing physician-diagnosed medical adverse applicable patient other voluntary more separate essential possible such other serious other adverse adverse legal adverse legal available available legal adverse Such local general same possible more adverse negative normal relevant abnormal short ear pre-existing physician-diagnosed medical adverse previous more prior additional old many religious philosophic mandatory personal vaccine-preventable serious effective common accurate specific other anti-vaccine sure common anti-vaccine socioeconomic other survival susceptible actual little significant direct modern present º- 1920-Present periodic real permanent wide other vaccine-preventable similar significant high least 15-year universal significant good few available most hard virtual recent other modern several dramatic same annual immediate major former low primary 2- 10-fold former anti-vaccine effective true such effective apparent effective Most routine 85-95 hypothetical high entire susceptible unvaccinated several high unvaccinated less most hot considerable hot dangerous other certain serious minor temporary little permanent adverse same several several larger coincidental highest first adverse relative hot best worst particular serious adverse legal modern adverse unsafe additional protective product-testing weekly unusual first unsafe healthy safe many hormful possible long-term safe much anti- genuine vast adverse minor temporary serious adverse few hard new vaccine-related little low moderate past same fair well-controlled other several likely decreased serious adverse many more serious 71-fold 4-fold due severe Continuous full full serious many clear many many more medical effective unconscionable low serious vaccine-related Vaccine-preventable true vaccine-preventable low other same few small few unvaccinated second small small susceptible immune successful successful irresponsible other same multiple different same hormful many foreign new numerous upper viral strep normal unlikely separate available scientific simultaneous multiple normal various American simultaneous such safe effective effective such greater adverse simultaneous routine single individual fewer practical several same possible vulnerable early various same several same fewer traumatic infectious available infectious infectious avian necessary human well-known necessary many different infectious adverse sensitive partial viral infectious transmissible other other “ such other other chronic other chronic other same similar higher healthy partial simian live oral adventitious independent inconclusive other Simian simian early human Simian early injectable experimental oral adventitious different positive few simian human human normal non-neoplastic human human many injectable several clinical oral early single fetal human such human fetal legal new fetal single human congenital early neurological preventable American safe effective more secondary such streptococcal healthy safe effective numerous rigorous clinical many adventitious monkey infectious simian lymphocytic viable microbial live oral free adventitious viral new infectious Other other sensitive more 1-800-232-2522 1-800-232-0233 Spanish Many same common other earlier persistent unwanted few unchanged such many oriental such adverse many alcoholic preservative mercuric thiosalicylic specific known adverse same small serious allergic serious greater serious more 1-800-232–2522 such current chronic regular sure safest possible other good scientific medical public serious infectious scientific theoretical general Other Spanish 1-800-232-0233 | real live single Spanish appropriate referral general 1-888-CDC-FAXX 1-888-232-3299 touch-tone 1-888-232-3299 same current available extra current available geographic recent latest international 1-877-FYI-TRIP 1-877-394-8747 toll-free other international toll-free 1-888-232-3299 10-month-old following oral many more single- definitive infectious various clinic popular two-sided such technical other excellent necessary best many new free electronic 800-232–2522 nipinfo new 800-232–2522 800-232-0233 available other easy-to-read federal 800-232-2522 foreign-language pneumococcal 510-849-5042 pneumococcal 612-676-5237 www.cdc.gov/nip- new latest medical more Vaccine-Preventable great large readable available 800-418-7246 eligible young other 28-page semiannual other vaccine-preventable primary general obstetrician- latest various new camera-ready copyright-free camera-ready CDC-reviewed e-mail 651-647-9131 receive periodic e-mail new new new important public personal preventable e-mail camera-ready copyright- free technical free free available available immigrant/refugee Vaccine-Preventable middle-school camera-ready copyright-free national many available exhaustive available many other adolescent vaccine-monitoring many free latest worth excellent primary infectious various 800-433-9016 official new more 800-433-9016 monthly excellent new free available 800-433-9016 state-specific educational available excellent official local educational twice-a-year jam-packed whole easier Regular latest new other low-cost Other appropriate higher Russian deductible full 651-647-9009 e-mail e-mail latest other newsworthy e-mail ” e-mail other immediate ” 651-647-9009 651-647-9131 new 2-month-old 1-day-old partici- many available solid necessary easy-to-read academic medical well-meaning available local 1-800-428-5331 available Vaccine-Preventable ubiquitous 50-100 communicable airborne direct live 12-18 susceptible susceptible likely high severe severe 4-5 natural clinical same whole fewer adverse least old least dose acceptable whole live high interim IPV-IPV-OPV-OPV inactivated post-vaccination 1-2 additional anti-HBSAg least routine healthy serious old least old chronic immediate live intra-nasal big antibiotic 60-70 effective invasive old less old 11-12 live severe Acceptable pregnant inactivated whole clinical high old high homosexual severe chronic common severe young physician 20-40 live oral common 49-68 effective 64-91 effective severe full other minimum minimum first available first maximum dose isn enough older common adverse attributable 3-5 live similar other severe allergic prior usual severe prudent few chronic gastrointestinal 329-3302 562-7802 329-3292 230-5817 Little 329-8275 329-8294 230-5855 661-2723 540-2065 329-8286 691-6118 329-8306 329-3255 329-8261 329-8262 586-8347 657-3158 586-8330 329-8303 524-0967 329-8269 329-8270 * 329-8282 329-8283 296-5593 329-8263 564-4553 329-3276 |MAINE 329-3271 564-4478 483-1900 Gillian 335-8159 329-3272 329-8264 Vaccine-Preventable 329-8284 526-5220 329-8287 329-8246 576-7751 271-4485 08625-0369 329-8249 329-8277 12237-0627 329-8250 329-8300 687-4800 715-6781 58505-0200 329-8288 329-8273 644-7740 10th 329-8278 329-8304 329-82.47 329-8267 741-3857 685-6749 329-8279 329-8280 329-8281 329-3290 538-9440 538-9450 329-8305 576-6418 558-1941 53701-0309 329-8274 329-3291 558-2188 011-684-633-5379 329-8296 011-671-734-1475 329-3028 329-8298 011-692-625-3432 329-8295 011-684-633-4606 011-671-734–7135 011-671-734–7160 011-671-734–7143 .248-4226 011-692-625-3480 011-691-320-2619 011-670–234–8930 Other Communicable 329-8253 011-670–234–8950 ext 011-160-680-1757 * sº- 642-25ll subjFCTTORECAll- —u-e-H ~~~~-I-2 assary 